Wojciech Schönemann,Agnieszka Ludwig-Słomczyńska,Łukasz Dudek,Marcin Król,Marco Farinone,Urszula Kulesza,Wojciech Jasnosz,Izabela Mac,Karol Zuchowicz,Katarzyna Wierzbicka,Aleksandra Buchcic-Szychowska,Andrzej Gondela,Anna Zagórska,Oliwia Matuszewska,Marta Sowińska,Marcin Nowogródzki,Marianna Girardi,Szymon Paluch,Svitlana Sukhomlinova,Agata Chłopek,Iana Levenets,Kamila Kozłowska-Tomczyk,Katarzyna Łagosz-Ćwik,Mateusz Stoszko,Szymon Woroszyło,Maciej Mikulski,Justyna Jabłońska,Magdalena Wiśniewska,Katarzyna Palus-Chramiec,Paulina Podkalicka-Gołda,Anita Janiga,Sylwia Sudoł-Tałaj,Magdalena Sieprawska-Lupa,Magdalena Miodek,Jacek Faber,Róża Starczak,Bozena Winnik,Agnieszka Świrska,Anna Kowal-Chwast,Dawid Gogola,Sanja Novak Ratajczak,Agata Dudek,Nilesh Gaud,Grzegorz Satała,Agata Stachowicz,Martin Swarbrick,Krzysztof Brzózka,Magdalena I. Zawadzka

Abstract:The synthetic lethality resulting from the inhibition of the WRN helicase protein has been observed in tumors characterized by high levels of microsatellite instability (MSI-H). This instability stems from a deficiency in the DNA mismatch repair (MMR) mechanisms, leading to the accumulation of DNA damage. This phenomenon is notably prevalent in 10-30% of colorectal, gastric, endometrial, and ovarian cancers. Specifically, the inhibition of WRN helicase activity induces DNA damage leading to cell cycle arrest and apoptosis exclusively in MSI-H cell lines. This selectivity underscores the therapeutic potential of WRN inhibitors, as they demonstrate efficacy against MSI-H cells while remaining non-toxic to microsatellite stable (MSS) cell lines. Ryvu is developing a chemical series of potent, selective WRN helicase inhibitors. Structure-based optimization facilitated the rapid expansion and delivery of a compound library with novel intellectual property (IP), demonstrating target engagement in cells and selective potency over other RecQ family members. The correlation between the cellular effect and selectivity upon treatment with these ligands was confirmed in the clonogenic assay, specifically in responder, microsatellite instable cell lines only, thereby leaving a substantial safety margin (>100x) relative to non-responder, microsatellite stable lines. Target engagement has been confirmed by dose dependent DNA damage pathway activation concomitant with WRN degradation in in vitro assays. The pharmacokinetic properties of these compounds are favorable for progressing to in vivo studies. The correlation between compound exposure and on-target effect was confirmed in PK/PD and efficacy studies in xenograft MSI-H cancer models. These data provide pharmacological proof-of-concept for the synthetic lethal effect of our inhibitors and support WRN inhibition as a new oncological therapy. Citation Format: Wojciech Schönemann, Agnieszka Ludwig-Słomczyńska, Łukasz Dudek, Marcin Król, Marco Farinone, Urszula Kulesza, Wojciech Jasnosz, Izabela Mac, Karol Zuchowicz, Katarzyna Wierzbicka, Aleksandra Buchcic-Szychowska, Andrzej Gondela, Anna Zagórska, Oliwia Matuszewska, Marta Sowińska, Marcin Nowogródzki, Marianna Girardi, Szymon Paluch, Svitlana Sukhomlinova, Agata Chłopek, Iana Levenets, Kamila Kozłowska-Tomczyk, Katarzyna Łagosz-Ćwik, Mateusz Stoszko, Szymon Woroszyło, Maciej Mikulski, Justyna Jabłońska, Magdalena Wiśniewska, Katarzyna Palus-Chramiec, Paulina Podkalicka-Gołda, Anita Janiga, Sylwia Sudoł-Tałaj, Magdalena Sieprawska-Lupa, Magdalena Miodek, Jacek Faber, Róża Starczak, Bozena Winnik, Agnieszka Świrska, Anna Kowal-Chwast, Dawid Gogola, Sanja Novak Ratajczak, Agata Dudek, Nilesh Gaud, Grzegorz Satała, Agata Stachowicz, Martin Swarbrick, Krzysztof Brzózka, Magdalena I. Zawadzka. Discovery of WRN inhibitors as targeted therapy in the treatment of microsatellite unstable (MSI-H) tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5942.

WRN inhibition leads to its chromatin-associated degradation via the PIAS4-RNF4-p97/VCP axis

Novel WRN Helicase Inhibitors Selectively Target Microsatellite Unstable Cancer Cells.

A Small-Molecule Inhibitor of WRN Selectively Kills MSI-H Cancer Cells and Phenocopies WRN Genetic Defects

Abstract 6590: Novel WRN helicase inhibitors selectively target microsatellite unstable cancer cells

PROTAC-mediated conditional degradation of the WRN helicase as a potential strategy for selective killing of cancer cells with microsatellite instability

Repeat expansions confer WRN dependence in microsatellite-unstable cancers

Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase

Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by Dntp Starvation

Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers

Targeting ATP-binding Site of WRN Helicase: Identification of Novel Inhibitors Through Pocket Analysis and Molecular Dynamics-Enhanced Virtual Screening

Synthetical lethality of Werner helicase and mismatch repair deficiency is mediated by p53 and PUMA in colon cancer

Abstract 5609: A WRN screening cascade to facilitate novel drug discovery

WRN Helicase: Is There More to MSI-H than Immunotherapy?

Abstract 7278: Discovery of a novel WRN inhibitor, ZM-3329 that efficiently inhibits MSI-H tumor growth

Abstract 3095: A high-throughput phenotypic screen to identify small molecule inhibitors of Werner helicase

Abstract 5942: Discovery of WRN inhibitors as targeted therapy in the treatment of microsatellite unstable (MSI-H) tumors

Challenges for the Discovery of non‐covalent WRN Helicase inhibitors

Abstract 3113: Development of HTS enzymatic assays for WRN helicase and exonuclease functions

Abstract 412: Discovery and preclinical characterization of ISM9342A, a novel, potent, and orally bioavailable WRN inhibitor that suppresses MSI-H tumor growth

Discovery of thiophen-2-ylmethylene bis-dimedone derivatives as novel WRN inhibitors for treating cancers with microsatellite instability

Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells